tbuckley/cabot-search huggingface dataset:
Neutrophil to lymphocyte ratio and response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Authors: Arnoud J. Templeton, Eitan Amir, Priya Aneja, Francisco Emilio Vera-Badillo, Thomas Hermanns, Mairead Geraldine McNamara, Daniel Yick Chin Heng, Jennifer J. Knox
Journal: Journal of Clinical Oncology (2014)

477 Background: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are markers of host inflammation and have prognostic value in many solid tumors. Here we aimed to explore the association of NLR and PLR with response to tyrosine kinase inhibitor (TKI) treatment in metastatic renal cell carcinoma (mRCC). Methods: Data from patients with mRCC treated at the Princess Margaret Cancer Centrein Toronto with a TKI as first-line treatment were retrospectively collected. The association of several variables with response to treatment (complete response [CR] or partial response [PR] vs. stable disease &gt; 3 months [SD] or progressive disease [PD]) was assessed by binary logistic regression. Significant variables were dichotomized and cut-offs selected by the area under the receiver operating characteristic (AUC) curve. Results: Data from 157 patients treated between 11/2004 and 09/2012 were analyzed. Median age at start of TKI treatment was 61 years and first-line treatment was sunitinib, sorafenib, and other in 49%, 43%, and 8% of patients, respectively. Best response was CR/PR, SD, and PD in 27%, 55%, and 18% patients. On multivariable analysis NLR &gt; 2.5 and Karnofsky Performance Status (KPS) &lt; 90% were associated with a lower likelihood of response and each allocated a score of 1 unit. Response rates for a score of 0, 1, or 2 were 45% (29-61%), 28% (17-38%), 10% (1-19%), respectively. PLR did not retain association with response in multivariable analysis. Conclusions: NLR and KPS are associated with response to TKI treatment in mRCC. Data from an external validation set will also be presented.
Polymorphisms of FcγRIIA, FcγRIIB, and FcγRIIIA and Therapeutic Response to Rituximab Combination Therapy in Patients with Waldenstrom's Macroglobulinemia.
Authors: Guang Yang, Christina Hanzis, Ping Gong, Sigitas Verselis, Edward A. Fox, Lian Xu, Bryan Ciccarelli, Yangsheng Zhou, Zachary Hunter, Jenny Sun, Xia Liu, Hsiuyi Tseng, Yang Cao, Robert Manning, Megan Lewicki, Thea Ioakimidis, Patricia Sheehy, Christopher J Patterson, Steven Treon
Journal: Blood (2009)
ECHOCARDIOGRAPHIC FEATURES, LEFT HEART EVENTS AND THE SPATIAL VENTRICULAR GRADIENT IN A CASE WITH INTERMITTENT TYPE A WOLFF-PARKINSON-WHITE SYNDROME
Authors: Kazutoshi Ishizawa, Akira Matsumori, Hisashi Yokoyama, Morihito Okada
Journal: Circulation (1978)

In a patient with intermittent type A Wolff-Parkinson-White (WPW) syndrome, the echocardiogram revealed late double peaked  anterior motions (the former in the late systole, the latter in the early diastole) of left ventricular posterior wall during WPW conduction. In the same condition, phonocardiographic and mechanocardiographic observations indicated a prolonged electromechanical interval, but the external isovolumic contraction time (EICT) and left ventricular ejection time/EICT ratio remained unaltered. In addition, definite but slight alteration in the spatial ventricular gradient was observed. These observations by non-invasive methods present additional informations supporting the concept that conduction abnormalities per se are not responsible for abnormalities of ventricular function unless there is severe underlying heart disease.
Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer
Authors: Alvin P Makohon-Moore, Ming Zhang, Johannes G Reiter, Ivana Bozic, Benjamin Allen, Deepanjan Kundu, Krishnendu Chatterjee, Fay Wong, Yuchen Jiao, Zachary A Kohutek, Jungeui Hong, Marc Attiyeh, Breanna Javier, Laura D Wood, Ralph H Hruban, Martin A Nowak, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein, Christine A Iacobuzio-Donahue
Journal: Nature Genetics (2017)
Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS
Authors: Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Cesare Astori, Marzia Varettoni, Ester Orlandi, Patrizia Zappasodi, Silvia Rizzi, Ilaria Ambaglio, Mario Lazzarino, Mario Cazzola
Journal: Blood (2010)
Cell-Derived Microparticle (C-MP) Profiles in Lymphoproliferative Disorders: Association of Elevated Red Cell Microparticles (RMP) with Thrombosis.
Authors: Vincenzo Fontana, J.Y. Wenche, Lawrence Horstman, Pamela Dudkiewicz, Joaquim Jimenez, Ahn S. Ahn
Journal: Blood (2007)
Additional important research priorities for bronchiectasis in China
Authors: Stefano Aliberti, Raja Dhar, Timothy R. Aksamit, Lucy Morgan, James D. Chalmers
Journal: European Respiratory Journal (2017)

We thank W. Guan and colleagues for highlighting important additional research priorities for bronchiectasis in China. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) research priorities “roadmap” published in the European Respiratory Journal was specifically developed to address the issue of research priorities from the point of view of European experts, and with this in mind, it is important to consider how these priorities may be different across different healthcare systems in differing areas of the world [1]. A new international consortium of bronchiectasis researchers has been launched <http://ow.ly/HfK4307adkV>
Health Insurance Deductibles and Their Associations With Out-of-Pocket Spending and Affordability Barriers Among US Adults With Chronic Conditions
Authors: Joel E. Segel, Jeffrey T. Kullgren
Journal: JAMA Internal Medicine (2017)

J. Frank Wharam, MB, BCh, BAO, MPH; Fang Zhang, PhD; Emma M. Eggleston, MD, MPH; Christine Y. Lu, PhD; Stephen Soumerai, ScD; Dennis Ross-Degnan, ScD
502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium
Authors: T.W-W. Chen, A. Pang, M.E. Puhaindran, M.M. Maw, H.H. Loong, V. Sriuranpong, C-C. Chang, S. Teo, S. Mingmalairak, T. Hirose, M. Endo, A. Kawai, M. Farid, S.H. Tan, W.L. Goh, R. Quek, J.C. Chan, A.K.C. Leung, R. Ngan
Journal: Annals of Oncology (2016)
Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial
Authors: Raf Bisschops, Sabine Tejpar, Hilde Willekens, Gert De Hertogh, Eric Van Cutsem
Journal: Endoscopy (2017)

Background and study aims (Virtual) chromoendoscopy detects more polyps than standard white-light endoscopy in patients with Lynch syndrome. Previous back-to-back trials did not randomize for the examination order, creating a possible bias in favor of chromoendoscopy. We aimed to assess the difference in polyp detection between high definition white-light endoscopy (HD-WLE) and virtual chromoendoscopy with I-SCAN in patients with Lynch syndrome. Patients and methods In this prospective, controlled trial, patients were randomized to either HD-WLE followed by I-SCAN (Group 1; n = 31) or I-SCAN followed by HD-WLE (Group 2; n = 30). Polyps found during the first pass were removed. The primary end point of the study was the difference in adenoma detection between HD-WLE and I-SCAN, expressed as the miss rate for adenomas for each technique. Results In Group 1, I-SCAN detected four additional patients with at least one adenoma, whereas HD-WLE did not increase the adenoma detection rate in Group 2 (relative risk [RR] 0.4; P = 0.08). In Group 1, five adenomas were detected and removed with HD-WLE and a second pass with I-SCAN detected a further eight adenomas. In Group 2, I-SCAN detected 15 adenomas and subsequent HD-WLE detected 2 additional adenomas. The adenoma miss rate was significantly higher for HD-WLE (62 %) compared with I-SCAN (12 %; RR 0.44, 95 % confidence interval [CI] 0.21 to 0.87; P = 0.007). The miss rate for lesions was 57 % and 24 %, respectively, and was significantly different in favor of I-SCAN (RR 0.54, 95 %CI 0.3 to 0.85; P = 0.005). The mean inspection time in both groups was not significantly different during first (485 vs. 536 seconds; 95 %CI - 139.91 to 33.34) or second pass (421 vs. 387 seconds; 95 %CI - 32.24 to 104.89). Conclusion Our data suggest that virtual chromoendoscopy with I-SCAN reduces the adenoma and polyp miss rate in patients with Lynch syndrome, independently of inspection time.ClinicalTrials.gov (NCT01823471).
Teens, Acne, and Oral Contraceptive Pills
Authors: Carolyn P. Neuhaus, Arielle R. Nagler, Seth J. Orlow
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
NUP98-NSD1 Related Gene Expression Signature Is Strongly Associated with a Poor Prognosis in Pediatric Acute Myeloid Leukemia
Authors: Norio Shiba, Hitoshi Ichikawa, Tomohiko Taki, Myoung-ja Park, Aoi Jo, Sachiyo Mitani, Tohru Kobayashi, Akira Shimada, Manabu Sotomatsu, Hirokazu Arakawa, Souichi Adachi, Akio Tawa, Keizo Horibe, Masahiro Tsuchida, Ryoji Hanada, Ichiro Tsukimoto, Yasuhide Hayashi
Journal: Blood (2012)
The Molecular Screening Using Multiplex Reverse Transcription Polymerase Chain Reaction and the Comparison with Cytogenetic Analysis in the Prognostic Stratification of Acute Leukemia
Authors: Young-Uk Cho, Hyun-Sook Chi, Seongsoo Jang, Eul-Ju Seo, Jung-Hee Lee, Je-Hwan Lee, Jong-Jin Seo, Kyoo-Hyung Lee, Chan-Jeoung Park
Journal: Blood (2008)
Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Lymphocytic Leukemia: a Long Term Analysis From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).
Authors: Mohamad Mohty, Jean-Paul Vernant, Ibrahim Yakoub-Agha, Didier Blaise, Gérard Socié, Catherine Cordonnier, Eric Deconinck, Jean-Henri Bourhis, François Guilhot, Agnes Buzyn, Norbert Ifrah, Denis Guyotat, Jean-Luc Harousseau, Laurent Sutton, Noel-Jean Milpied, Mauricette Michallet
Journal: Blood (2009)
ASSESSMENT OF THE RELATIONSHIP BETWEEN SERUM VASCULAR ADHESION PROTEIN (VAP)-1 AND SEVERITY OF CALCIFIC AORTIC VALVE STENOSIS
Authors: Huseyin Altug Cakmak, Serkan Aslan, Mehmet Erturk, Vesile Ornek, Aydin R. Tosu, Ali K. Kalkan, Derya Ozturk, Omer Tasbulak, Yalcin Avci, Mehmet Gul
Journal: Journal of the American College of Cardiology (2016)
Some Notable Epidemics
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial
Authors: Maliha Khan, Bodden Kristy, Tapan Kadia, Alessandra Ferrajoli, Yesid Alvarado, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Guillermo Garcia-Manero, Courtney DiNardo
Journal: Blood (2015)
Immunoglobulin-Like Transcript 2 (ILT2) Is Not Differentially Expressed in MGUS and Myeloma, but Appears To Be Downregulated at an Earlier Stage of Plasma Cell Disease.
Authors: Martin Schreder, Wolfgang Huebl, Gudrun Koch, Kathrin Strasser-Weippl, Niklas Zojer, Heinz Ludwig
Journal: Blood (2006)
Impact on Quality of Life of Postconsolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in Acute Myelogenous Leukemia.
Authors: Elisabeth Wallhult, John Whisnant, Jacob M. Rowe, Jeff Szer, Dileep Bhagwat, Kristoffer Hellstrand, Bo I. Nilsson, Mats L. Brune
Journal: Blood (2007)
Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab
Authors: Sarit Assouline, Valeria Buccheri, Alain Delmer, Gottfried Doelken, Gianluca Gaidano, Christine McIntyre, Mike Brewster, Florence Hourcade-Potelleret, Pakeeza Sayyed, Xavier Badoux
Journal: Blood (2012)
Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation.
Authors: Amro Aboukameel, Anton-Scott Goustin, Ramzi Mohammad, Claudia Zuany-Amorim, Marie-Christine Bissery, Ayad M. Al-Katib
Journal: Blood (2007)
Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.
Authors: Nicolai Wagtmann, Pascale Andre, Stefan Zahn, Pieter Spee, Nicolas Anfossi, Laurent Gauthier, Bradley W. Blaser, Michael A. Caligiuri, Marusca Capanni, Loredana Ruggeri, Andrea Velardi, Francois Romagne
Journal: Blood (2007)
Telomerase Activity and Telomere Length of CD4+CD25+ Regulatory T-Cells under Conditions of In Vitro and In Vivo Expansion.
Authors: Dominik G.F. Wolf, Anna M. Wolf, Christian Koppelstaetter, Holger F. Rumpold, Gert Mayer, Guenther A. Gastl, Eberhard Gunsilius, Herbert Tilg
Journal: Blood (2004)
PWE-154 Endoscopic Ultrasound (EUS) Is Superior to CT/MRI in The Detection of Pancreatic Neuro-Endocrine Tumours (PNETS) As A Baseline Assessment of Patients with Multiple Endocrine Neoplasia Type I (MEN1)
Authors: I Koumoutsos, C Chia, I Nasr, S DeMartino, J Meenan
Journal: Gut (2016)

<h3>Introduction</h3> Early identification of pNETs is a key element to reducing morbidity and mortality in MEN1 patients. Prognosis is associated with tumour size and many pNETs are small subcentimetre lesions and only become symptomatic when the tumour is large. Conventional radiology is suboptimal in detecting such lesions, thus missing the window to remove them at an earlier stage. We compared: (a) linearEUS detection of pNETs in patients with confirmed MEN1 vs triple-phase contrast-enhanced CT/MRI pancreas and (b) incremental benefit of EUS to cross-sectional imaging for detection of small pNETs and quantity of pNETs in this cohort <h3>Methods</h3> Between Jan 2008- Oct 2015, a total of 20 patients with clinically confirmed MEN1 underwent baseline assessment with EUS, CT/MRI and biochemical screening. Data were retrospectively retrieved from the hospital electronic records database. Statistical analysis was performed using SPSS v20 on the size and number of pNET detection by EUS and CT/MRI using the Wilcoxon Signed Rank Test and McNemar Chi-square <h3>Results</h3> A total of 28 EUS procedures and an equal number of cross sectional imaging (CT/MRI) were performed. pNETs were identified in 95% of all 20 MEN1 cases. Overall median pNET size was 7.1 mm on EUS and 14.5 mm on CT/MRI (p = 0.007). Median value for smallest pNETs detected by EUS was 4.6 mm and 12.7 mm on CT/MRI (p = 0.001). EUS detected more pancreatic lesions/pNETs compared to CT/MRI (p &lt; 0.001) in 25 of the 28 procedures (89.3% more). The remaining 3 procedures showed equal numbers of pNETs detection by both modalities. The interquartile range (IQR) for smallest pNET detected by EUS was 3.0–5.0 mm while IQR for CT/MRI lies between 8.3 mm-14.8mm. EUS detected all 100% cases of pNETs in our series of MEN1 compared to CT/MRI imaging alone which detected 57.9% cases (p = 0.008). 14 of 20 patients had FNA performed with a positive yield of 85.7%. In 50% of patients, pNET measured ≤10 mm. Conclusions In MEN1 patients, CT/MRI underestimated the presence of pNETs in approximately half of all cases compared to EUS and was not able to identify small pNETs (&lt; 8 mm) in all but one case. <h3>Conclusion</h3> EUS offers higher sensitivity than cross sectional imaging (CT/MRI) in terms of detecting the number of positive pNET cases as well as a greater number of pancreatic lesions especially subcentimetre ones. EUS should be considered a standard tool in the algorithm for MEN1 workup, instead of an adjunct reserved for diagnostic dilemmas <h3>Disclosure of Interest</h3> None Declared
Constitutive Activation of Ras and Mitogen-Activated Protein Kinase (MAPK/ERK) in LGL Leukemia Unrelated to Activating Mutations in N and KRas Genes.
Authors: Jeffrey S. Painter, Angela Costellanos, Fanqi Bai, Sheng Wei, Thomas P. Loughran, P.K. Epling-Burnette
Journal: Blood (2007)
Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2–WNT Signaling Axis
Authors: Srinivas Nandana, Manisha Tripathi, Peng Duan, Chia-Yi Chu, Rajeev Mishra, Chunyan Liu, Renjie Jin, Hironobu Yamashita, Majd Zayzafoon, Neil A. Bhowmick, Haiyen E. Zhau, Robert J. Matusik, Leland W.K. Chung
Journal: Cancer Research (2017)

Identification of factors that mediate visceral and bone metastatic spread and subsequent bone remodeling events is highly relevant to successful therapeutic intervention in advanced human prostate cancer. TBX2, a T-box family transcription factor that negatively regulates cell-cycle inhibitor p21, plays critical roles during embryonic development, and recent studies have highlighted its role in cancer. Here, we report that TBX2 is overexpressed in human prostate cancer specimens and bone metastases from xenograft mouse models of human prostate cancer. Blocking endogenous TBX2 expression in PC3 and ARCaP
Response to eLetter: ‘Infections in giant cell arteritis and therapeutic implications’ by Moiseev <i>et al</i>
Authors: Rennie L Rhee, Peter C Grayson, Peter A Merkel, Gunnar Tomasson
Journal: Annals of the Rheumatic Diseases (2017)

Infections in giant cell arteritis and therapeutic implications' by Moiseev et alWe thank Professor Moiseev and colleagues for showing their interest in our work. 1 2While we agree that our study does not completely refute the link between varicella zoster virus (VZV) and giant cell arteritis (GCA), we feel that stronger evidence of a link between VZV and GCA are needed before clinical trials are conducted in which patients with GCA are given antiviral therapy.If VZV, whether clinically overt, subclinical or latent, triggers the onset of GCA, we would have expected a stronger association between herpes zoster and GCA compared with the association of other infections with GCA.Although outside the scope of our study, we agree that the risk of infection following the institution of immunosuppressive therapy, including biological agents, for GCA is extremely important and needs to be further defined.
Ceramide Kinase Promotes Store Dependent Ca2+ Signals and Enhances Phagolysosomal Fusion in COS-1 Cells.
Authors: Vania T. Hinkovska-Galcheva, Andrea J. Clark, Andrei L. Kindzelskii, Susan M. VanWay, JiBiao Huang, Thomas P. Shanley, James A. Shayman, Howard R. Petty, Laurence A. Boxer
Journal: Blood (2006)
ACTR-05. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
Authors: Tomokazu Aoki, Yoshiki Arakawa, Tetsuya Ueba, Masashi Oda, Namiko Nishida, Yukinori Akiyama, Tetsuya Tsukahara, Koichi Iwasaki, Nobuhiro Mikuni, Susumu Miyamoto
Journal: Neuro-Oncology (2016)

The aim of this phase I/II study was to examine the efficacy and toxicity profile of TMZ plus nimustine (ACNU), which is one of nitrosoureas for malignant gliomas. Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled on the phase I/II study. In phase I, the maximum-tolerated dose (MTD) by TMZ (150mg/m2/day) (Day1-5) plus various doses of ACNU (30,35,40,45 mg/m2/day) (Day15) per 4 weeks was defined on a standard 3+3 design. In phase II including the cohort 3 (MTD) of phase I, these therapeutic activity and safety of this regimen were evaluated. Forty-nine patients were enrolled. Their median age was 50 years-old. Eighty percent of patients (39/49 cases) had a KPS of 70–100. These histologies were 73% (36 cases) glioblastoma, 22% (11 cases) anaplastic astrocytoma, 4% (2 cases) anaplastic oligodendroglioma. In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150/mg/m2) plus ACNU (40mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients (14 of 40) experienced grade 3 or 4 toxicities, mainly hematologic. The overall response rate was 11% (4/37). Sixty-eight percent (25/37) had stable disease. Twenty-two percent (8/37) showed progression. Progression free survival (PFS) at 6 and 12 month were 24% (95%CI, 12–35%) and 8% (95%CI, 4–15%). Median PFS was 13 months (95%CI, 9.2–17.2months). Overall survival (OS) at 6 and 12 were 78% (95%CI, 67–89%) and 49% (95%CI, 33–57%). Median OS was 11.8 months (95%CI, 8.2–14.5months). This phase I/II study showed a moderate toxicity in hematology and may has a promising efficacy in OS, without inferiority in PFS, comparing with other studies. This regimen could be an option for recurrent malignant gliomas, though further clinical studies are warranted.
Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Adam Ceroi, Francine Garnache-ottou, Anne Roggy, Fanny Angelot-Delettre, Laure Philippe, Afag Asgarova, Francis Bonnefoy, Cécile Chagué, Sabeha Biichle, Jean-Paul Remy-Martin, Claude Preudhomme, Christophe Roumier, Elizabeth Macintyre, Laurent Lagrost, David Masson, Philippe Saas
Journal: Blood (2015)
MYC Protein Expression Correlates with C-MYC Transcriptional Activity in Absence of Gene Rearrangement in Diffuse Large B-Cell Lymphoma
Authors: Anna Misyurina, Vsevolod Andreevich Misyurin, Andrey Vitalievich Misyurin, Sergey Kirillovich Kravchenko, Alla M. Kovrigina, Elena Alexandrovna Baryakh, Vladimir Ivanovich Vorobiev, Valeri G. Savchenko
Journal: Blood (2015)
Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study
Authors: T. Huwyler, L. Lenggenhager, M. Abbas, K. Ing Lorenzini, S. Hughes, B. Huttner, A. Karmime, I. Uçkay, E. von Dach, P. Lescuyer, S. Harbarth, A. Huttner
Journal: Clinical Microbiology and Infection (2017)
Characterization of the Effects of Pim Kinase Inhibition on Multiple Oncogene-Driven Cell Lines
Authors: Stefan David Gross, John E Robinson, Shelley Allen, April Cox, Walt E DeWolf, Sarah Galbraith, Patrice Lee, Christine Lemieux, Joseph P Lyssikatos, Fredrik Marmsater, Matthew Martinson, Mark C Munson, Ross D Wallace, Rich Woessner, John Zuzack, James Winkler, Kevin Koch
Journal: Blood (2008)